Is the business good?
How good a business is STOK?
Stoke Therapeutics, Inc. keeps −577% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−577%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +6.2%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 452%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2022 | −841% |
| FY2023 | −1307% |
| FY2024 | −277% |
| FY2025 | −11% |
Details›
- Operating margin12 months to Q1 2026
- −577%
- Net margin12 months to Q1 2026
- −529%
- Free cash flow margin
- −460%
- R&D as % of revenue
- 452%
- Revenue, trailing twelve months
- $32M
- Free cash flow, trailing twelve months
- −$148M
- Net income, trailing twelve months
- −$170M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.